NSE: VIVIMEDLAB · BSE: 532660
VIVIMED LABS LIMITED
Manufactures pharmaceutical dosages at four plants in Hyderabad, Haridwar, Kashipur, and Bidar, with 352 employees reported as part of the insolvency filings. Standalone FY25 revenue is reported at ₹116.269 crore, while a related filing cited FY25 revenue of ₹103.6 crore against ₹136.8 crore in FY24; standalone revenue for the nine months ended December 2025 was ₹48.23 crore. The cost structure is materials-heavy at 49.7% of revenue, followed by employee costs at 24.4% and other opex at 34.9% of revenue. The NCLT Bengaluru Bench admitted the company into Corporate Insolvency Resolution Process on April 15, 2026, following a petition by Blue Cube Germany Assets GmbH, an operational creditor, for unpaid debt of ₹32.79 crore from chemical supplies made in 2012-2014. The board has been suspended, an Interim Resolution Professional has been appointed, and a CBI investigation is pending; the statutory auditor has flagged going-concern uncertainty, unrecorded interest of ₹626 million, and confirmed that all loans are non-performing assets. AR · MarketPing reader · 2026-08-02
Revenue streams, as the annual report describes them. sale. Small pharma dosage manufacturer under corporate insolvency resolution
Exhibit 1: Financial summary, FY21–FY25 (all audited; no estimate years)
| ₹ crore · consolidated | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | 861 | 237 | 187 | 149 | 116 |
| EBITDA (ex other income) | 24 | (8) | (187) | (33) | (33) |
| margin % | 2.8 | (3.4) | (100.1) | (22.4) | (28.2) |
| Owners' profit | (78) | 0 | (328) | 0 | — |
| EPS, as reported (₹) | (18.76) | (8.16) | (39.62) | (5.48) | (3.85) |
| ROE % · ROCE % | (18.0) · (2.3) | (18.6) · (2.8) | (833.4) · (52.3) | 832.2 · (8.0) | — · (5.5) |
| Debt / equity (x) | 0.59 | 0.76 | 9.60 | (69.02) | — |
| Cash from operations | 567 | (658) | 14 | (24) | (11) |
| Capex | 0 | 0 | (1) | 0 | (5) |
Exhibit 2: Quarterly performance, last 8 quarters
| ₹ crore | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 39 | 29 | 25 | 37 | 26 | 21 | 21 | 16 |
| Profit before tax | 7 | (8) | (5) | (6) | (5) | (5) | (7) | (17) |
| Net profit | 5 | (8) | (5) | (6) | — | (5) | (7) | (17) |
| EPS (₹) | 0.64 | (0.99) | (0.60) | (0.72) | (0.67) | (0.66) | (0.88) | (0.88) |
Exhibit 3: Filings of the last 90 days, with the measured price reaction
| Date · filing | Category | Importance | Next day % | 5-day % |
|---|---|---|---|---|
| 22 Oct 2026 · Exchange seeks clarification on modified audit opinion disclosure | regulatory legal | high | — | — |
| 15 Oct 2026 · Vivimed Labs FY26 results filed under CIRP, auditor gives qualified opinion | results | high | — | — |
| 28 Sept 2026 · Vivimed Labs 8th Committee of Creditors meeting scheduled for Sep 29, 2026 | regulatory legal | high | — | — |
| 26 Sept 2026 · 8th Committee of Creditors meeting scheduled for Sept 29, 2026 | regulatory legal | critical | — | — |
| 26 Sept 2026 · Vivimed Labs CoC seeks 3-month extension for FY26 AGM | regulatory legal | medium | — | — |
| 23 Sept 2026 · Trading window closure from Oct 1 for Q2 results | compliance | minimal | — | — |
| 8 Sept 2026 · Vivimed Labs 7th CoC meeting scheduled for September 10, 2026 | regulatory legal | high | — | — |
| 17 Aug 2026 · Vivimed Labs 6th Committee of Creditors meeting on August 18, 2026 | regulatory legal | high | — | — |
| 31 Jul 2026 · NSE seeks clarification from Vivimed Labs on Dec-2025 quarter results | regulatory legal | high | — | — |
| 22 Jul 2026 · Vivimed Labs reports nil re-lodgement transfer requests for June 2026 | compliance | minimal | — | — |
How to read this document
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions | an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
Sources, method and disclosures
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.